UNC2250
Based on 4 publication(s) in Google Scholar
UNC2250 is a potent and selective Mer inhibitor with an IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 1493694-70-4
- Formula: C24H36N6O2
- Molecular Weight:440.58
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) UNC2250
More-
WB
Biological Activity
|
Axl |
Mer |
UNC2250 (5-500 nM; 1 hour) inhibits Mer phosphorylation in 697 B-ALL cells with an IC50 value of 9.8 nM[1].
UNC2250 efficiently inhibits ligand-dependent phosphorylation of a chimeric protein consisting of the extracellular and transmembrane domains of the epidermal growth factor (EGF) receptor and the intracellular tyrosine kinase domain of Mer[1].
UNC2250 incubation inhibits colony formation in soft agar cultures of the BT-12 rhabdoid tumor and the Colo699 NSCLC cell lines[1] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:697 B-ALL cells
-
Concentration:5, 10, 20, 50, 100, 250, 500 nM
-
Incubation Time:1 hour
-
Result:Inhibits Mer phosphorylation in 697 B-ALL cells with an IC50 value of 9.8 nM.
Chemical Information
-
CAS No. 1493694-70-4
-
Appearance Solid
-
Molecular Weight 440.58
-
Formula C24H36N6O2
-
Color Light yellow to yellow
-
SMILES
CCCCNC1=NC(N[C@@H]2CC[C@@H](O)CC2)=C(C3=CC=C(CN4CCOCC4)C=N3)C=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway. [Abstract]2018 Jul 30;8(15):4262-4278. PMID: 30128052
UNC2250 purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]
BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of TAM receptor (LDC1267 at 1 µM, UNC2250 at 5 µM, R428 at 5 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.
-
Adv Sci (Weinh)
Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [Abstract]2025 Nov 21:e12508. PMID: 41271556 -
Int J Biol Macromol
Omentin-1 promotes diabetic wound healing by regulating macrophage efferocytosis and M2 polarization. [Abstract]2026 Feb:347:150757. PMID: 41654047 -
Cell Prolif
Tetrahedral Framework Nucleic Acid Relieves Sepsis-Induced Intestinal Injury by Regulating M2 Macrophages. [Abstract]2025 Jan 22:e13803. PMID: 39844345
Solvent & Solubility
0.1 M HCl : 12.5 mg/mL (28.37 mM; ultrasonic and adjust pH to 3 with HCl)
DMSO : ≥ 10 mg/mL (22.70 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 20% HS-15 70% Saline
Solubility: ≥ 1 mg/mL (2.27 mM); Clear solution
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang, W., et al., Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem, 2013. 56(23): p. 9683-92. [Content Brief]
[2]. Xiaodong Wang, et al. Pyrimidine compounds for the treatment of cancer.WO2013177168A1.
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.1 M HCl | 1 mM | 2.2697 mL | 11.3487 mL | 22.6974 mL | 56.7434 mL |
| 5 mM | 0.4539 mL | 2.2697 mL | 4.5395 mL | 11.3487 mL | |
| 10 mM | 0.2270 mL | 1.1349 mL | 2.2697 mL | 5.6743 mL | |
| 15 mM | 0.1513 mL | 0.7566 mL | 1.5132 mL | 3.7829 mL | |
| 20 mM | 0.1135 mL | 0.5674 mL | 1.1349 mL | 2.8372 mL | |
| 0.1 M HCl | 25 mM | 0.0908 mL | 0.4539 mL | 0.9079 mL | 2.2697 mL |